Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes

Current Drug Metabolism

Volumn 13, Issue 5, 2012, Pages 599-614

  Wu, Jing Jing ^a,b   Ai, Chun Zhi ^a   Liu, Yong ^a   Zhang, Yan Yan ^a   Jiang, Miao ^c   Fan, Xu Ran ^a   Lv, Ai Ping ^c   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Cytochrome P450 efficacy; Phytochemicals; TCM; Toxicity

Indexed keywords

ACONITINE; APIGENIN; BERBERINE; BIOCHANIN A; CARDAMONIN; CORYNOLIN; DAIDZEIN; DIOSMETIN; GALANGIN; GENISTEIN; GINSENOSIDE RF; GINSENOSIDE RG 2; GINSENOSIDE RH 1; HESPERETIN; HYPACONITINE; ISOKAEMPFERIDE; KAEMPFEROL; LIQUIRITIGENIN; MENTHOFURAN; MESACONITINE; NARINGENIN; PEONOL; PLANT MEDICINAL PRODUCT; PULEGONE; RESVERATROL; RUTAECARPINE; SCHIZANDRIN; SILIBININ; TAMARIXETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CHINESE MEDICINE; DRUG ACTIVITY; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHARMACODYNAMICS; PRESCRIPTION; SALVIA MILTIORRHIZA;

EID: 84861913662     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211209050599     Document Type: Article

References (167)

1. Blanck, H. M.; Wheaton, A. G.; Gizlice, Z.; Reyes, M. Medicinal herb use in a population-based survey of adults: prevalence and frequency of use, reasons for use, and use among their children. Ann. Epidemiol., 2005, 15 (9), 678-685.
2. Zhou, S. F.; Zhou, Z. W.; Li, C. G.; Chen, X.; Yu, X. Y.; Xue, C. C.; Herington, A. Identification of drugs that interact with herbs in drug development. Drug Discov. Today, 2007, 12 (15-16), 664-673.
3. Nebert, D. W.; Russell, D. W. Clinical importance of the cytochromes P450. Lancet, 2002, 360 (9340), 1155-1162.
4. Guengerich, F. P.; Wu, Z. L.; Bartleson, C. J. Function of human cytochrome P450s: Characterization of the orphans. Biochem. Biophys. Res. Commun., 2005, 338 (1), 465-469.
5. Ingelman-Sundberg, M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol., 2004, 197 (3), 142-142.
6. Nettleton, D. O.; Einolf, H. J. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development. Curr. Top. Med. Chem., 2011, 11 (4), 382-403.
7. Lake, B. G.; Price, R. J.; Giddings, A. M.; Walters, D. G. In vitro assays for induction of drug metabolism. Methods Mol. Biol., 2009, 481, 47-58.
8. Tracy, T. S., Atypical cytochrome p450 kinetics: implications for drug discovery. Drugs R D, 2006, 7 (6), 349-363.
9. de Graaf, C.; Vermeulen, N. P.; Feenstra, K. A. Cytochrome p450 in silico: an integrative modeling approach. J. Med. Chem., 2005, 48 (8), 2725-2755.
10. Foti, R. S.; Wahlstrom, J. L. Prediction of CYP-mediated drug interactions in vivo using in vitro data. IDrugs, 2008, 11 (12), 900-905.
11. Grime, K.; Riley, R. J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab., 2006, 7 (3), 251-264.
12. Foster, B. C.; Arnason, J. T.; Briggs, C. J. Natural health products and drug disposition. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 203-226.
13. Izzo A.A, E. E. Interactions Between Herbal Medicines and Prescribed Drugs. Drugs, 2009, 69 (13), 1777-1798.
14. Bush TM, R. K., Holloway SW, Sanchez-Yamamoto DS, Allen BL, Lam T, So BK, Tran DH, Greyber ER, Kantor S, Roth LW. Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey Alternat. Ther. Health Med., 2007, 13, 30-35.
15. Kennedy J, W. C., Wu CH. Patient disclosure about herb and supplement use among adults in the US. Evid Based Complement Alternat. Med., 2008, 5, 451-456.
16. Cai, Y.; Chen, J.; Jiang, J.; Cao, W.; He, L. Zhen-wu-tang, a blended traditional Chinese herbal medicine, ameliorates proteinuria and renal damage of streptozotocin-induced diabetic nephropathy in rats. J. Ethnopharmacol., 2010, 131 (1), 88-94.
17. Wang, A. X.; Hu, Y.; Liu, H. X.; Qi, X. Y.; Liu, Y.; Tu, C. X.; Yang, L. C5-Hydroxylation of liquiritigenin is catalyzed selectively by CYP1A2. Xenobiotica, 2011, 41 (5), 349-357.
18. Ma, X. C.; Ning, J.; Ge, G. B.; Liang, S. C.; Wang, X. L.; Zhang, B. J.; Huang, S. S.; Li, J. K.; Yang, L. Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human. Drug Metab. Dispos., 2011, 39 (4), 675-682.
19. Fang, Z. Z.; Zhang, Y. Y.; Ge, G. B.; Liang, S. C.; Sun, D. X.; Zhu, L. L.; Dong, P. P.; Cao, Y. F.; Yang, L. Identification of Cytochrome P450 (CYP) Isoforms involved in the Metabolism of Corynoline, and Assessment of its Herb-Drug Interactions. Phytother. Res., 2011, 25 (2), 256-263.
20. Cao, Y. F.; Zhang, Y. Y.; Li, J.; Ge, G. B.; Hu, D.; Liu, H. X.; Huang, T.; Wang, Y. C.; Fang, Z. Z.; Sun, D. X.; Huo, H.; Yin, J.; Yang, L. CYP3A catalyses schizandrin biotransformation in human, minipig and rat liver microsomes. Xenobiotica, 2010, 40 (1), 38-47.
21. Zhang, Y. Y.; Liu, Y.; Zhang, J. W.; Ge, G. B.; Liu, H. X.; Wang, L. M.; Sun, J.; Yang, L. C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes. Xenobiotica, 2009, 39 (12), 903-914.
22. Zhang, Y. Y.; Liu, Y.; Zhang, J. W.; Ge, G. B.; Wang, L. M.; Sun, J. ; Yang, L. Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica, 2009, 39 (4), 283-292.
23. Liu, H. X.; Hu, Y.; Liu, Y.; He, Y. Q.; Li, W. ; Yang, L. CYP1A2 is the major isoform responsible for paeonol O-demethylation in human liver microsomes. Xenobiotica, 2009, 39 (9), 672-679.
24. Liang, S. C.; Ge, G. B.; Liu, H. X.; Zhang, Y. Y.; Wang, L. M.; Zhang, J. W.; Yin, L.; Li, W.; Fang, Z. Z.; Wu, J. J.; Li, G. H.; Yang, L. Identification and characterization of human UDPglucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin. Drug Metab. Dispos., 2010, 38 (6), 973-980.
25. He, Y. Q.; Liu, Y.; Zhang, B. F.; Liu, H. X.; Lu, Y. L.; Yang, L.; Xiong, A. Z.; Xu, L. L.; Wang, C. H.; Yang, L.; Wang, Z. T. Identification of the UDP-Glucuronosyltransferase Isozyme Involved in Senecionine Glucuronidation in Human Liver Microsomes. Drug Metab. Dispos., 2010, 38 (4), 626-634.
26. Liu, H. X.; Liu, Y.; Zhang, J. W.; Li, W.; Liu, H. T.; Yang, L., UDP-glucuronosyltransferase 1A6 is the major isozyme responsible for protocatechuic aldehyde glucuronidation in human liver microsomes. Drug Metab. Dispos., 2008, 36 (8), 1562-1569.
27. Li-Weber, M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev., 2009, 35 (1), 57-68.
28. Nowack, R. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond! Nephrology (Carlton), 2008, 13 (4), 337-347.
29. Chan, E.; Tan, M.; Xin, J.; Sudarsanam, S.; Johnson, D. E. Interactions between traditional Chinese medicines and Western therapeutics. Curr. Opin. Drug Discov. Devel., 2010, 13 (1), 50-65.
30. Delgoda R, W. A. G. herbal interactions involving cytochrome P450 enzymes: A Mini Review. Toxicol. Rev., 2004, 23 (4), 239-249.
31. Zheng, G.; Jiang, M.; He, XJ.; Zhao, J.; Guo, HT.; Chen G.; Zha, QL.; Lv, AP. Discrete derivative: a data slicing algorithm for exploration of sharing biological networks between rheumatoid arthritis and coronary heart disease. BioData Min., 2011, 4, 18.
32. Guengerich, F. P. Human cytochrome P450 enzymes. In: Ortiz de Montellano P, editor. Cytochrome P450. 2nd ed. New York: Plenum Press 1995, 473-575.
33. Shapiro, L. E.; Shear, N. H. Drug interactions: Proteins, pumps, and P-450s. J. Am. Acad. Dermatol., 2002, 47 (4), 467-484.
34. Guengrich, F. P. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 1-17.
35. Guengerich, F. P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 2006, 8 (1), E101-E111.
36. Luoma, P. V. Cytochrome P450 and gene activation - from pharmacology to cholesterol elimination and regression of atherosclerosis. Eur. J. of Clin. Pharmacol., 2008, 64 (9), 841-850.
37. Zhang, Y. Y.; Yang, L. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications. Expert Opin. Drug Metab. Toxicol., 2009, 5 (6), 621-629.
38. Bian, Z.; Shang, H.; Cheng, C.; Wu, T.; Li, Y.; Zhang, B. Review of adverse reactions to injections of Chinese materia medica. J. Evid. Based Med., 2010, 3 (2), 88-94.
39. Liang, W.; Kuang, J. Investigation on the Adverse Drug Reactions and Adverse Events of 18 Traditional Chinese Medical Injections by Data Analysis. China Licensed Pharmacist 2011, 1, 4-9.
40. Liang, Y. Z.; Xie, P. S.; Chan, K. Perspective of chemical fingerprinting of Chinese herbs. Planta Medica, 2010, 76 (17), 1997-2003.
41. Attele, A. S.; Wu, J. A.; Yuan, C. S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol., 1999, 58 (11), 1685-1693.
42. Christensen, L. P. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res., 2009, 55, 1-99.
43. Jia, L.; Zhao, Y. Current evaluation of the millennium phytomedicine - ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Current Med. Chem., 2009, 16 (19), 2475-2484.
44. Jia, L.; Zhao, Y.; Liang, X. J. Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr. Med. Chem., 2009, 16 (22), 2924-2942.
45. Liu, H.; Yang, J.; Du, F.; Gao, X.; Ma, X.; Huang, Y.; Xu, F.; Niu, W.; Wang, F.; Mao, Y.; Sun, Y.; Lu, T.; Liu, C.; Zhang, B.; Li, C. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab. Dispos. 2009, 37 (12), 2290-2298.
46. Xie, H. T.; Wang, G. J.; Sun, J. G.; Tucker, I.; Zhao, X. C.; Xie, Y. Y.; Li, H.; Jiang, X. L.; Wang, R.; Xu, M. J.; Wang, W. High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci., 2005, 818 (2), 167-173.
47. Bae, E. A.; Han, M. J.; Kim, E. J.; Kim, D. H. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch. Pharm. Res., 2004, 27 (1), 61-67.
48. Lai, L.; Hao, H.; Liu, Y.; Zheng, C.; Wang, Q.; Wang, G.; Chen, X. Characterization of pharmacokinetic profiles and metabolic pathways of 20(S)-ginsenoside Rh1 in vivo and in vitro. Planta Medica, 2009, 75 (8), 797-802.
49. Qian, T.; Cai, Z.; Wong, R. N.; Mak, N. K.; Jiang, Z. H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci., 2005, 816 (1-2), 223-232.
50. Qian, T.; Cai, Z.; Wong, R. N.; Jiang, Z. H. Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun. Mass Spectrom., 2005, 19 (23), 3549-3554.
51. Yang, L.; Deng, Y.; Xu, S.; Zeng, X. In vivo pharmacokinetic and metabolism studies of ginsenoside Rd. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci., 2007, 854 (1-2), 77-84.
52. Kasai, R.; Hara, K.; Dokan, R.; Suzuki, N.; Mizutare, T.; Yoshihara, S.; Yamasaki, K. Major metabolites of ginseng sapogenins formed by rat liver microsomes. Chem. Pharm. Bull., 2000, 48 (8), 1226-1227.
53. Hao, H.; Lai, L.; Zheng, C.; Wang, Q.; Yu, G.; Zhou, X.; Wu, L.; Gong, P.; Wang, G. Microsomal cytochrome p450-mediated metabolism of protopanaxatriol ginsenosides: metabolite profile, reaction phenotyping, and structure-metabolism relationship. Drug Metab. Dispos., 2010, 38 (10), 1731-1739.
54. Tang, L.; Ye, L.; Lv, C.; Zheng, Z.; Gong, Y.; Liu, Z. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Toxicol. Lett., 2011, 202 (1), 47-54.
55. Ye, L.; Wang, T.; Yang, C.; Tang, L.; Zhou, J.; Lv, C.; Gong, Y.; Jiang, Z.; Liu, Z. Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species. Toxicol. Lett., 2011, 204 (1), 81-91.
56. Ye, L.; Tang, L.; Gong, Y.; Lv, C.; Zheng, Z.; Jiang, Z.; Liu, Z. Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine. Xenobiotica, 2011, 41 (1), 46-58.
57. Li, Y.; Ren, G.; Wang, Y. X.; Kong, W. J.; Yang, P.; Wang, Y. M.; Li, Y. H.; Yi, H.; Li, Z. R.; Song, D. Q.; Jiang, J. D. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J. Transl. Med., 2011, 9, 62.
58. Fang, Z. Z.; Zhang, Y. Y.; Ge, G. B.; Liang, S. C.; Sun, D. X.; Zhu, L. L.; Dong, P. P.; Cao, Y. F.; Yang, L. Identification of Cytochrome P450 (CYP) Isoforms involved in the Metabolism of Corynoline, and Assessment of its Herb-Drug Interactions. Phytother. Res., 2011, 25 (2), 256-263.
59. Ueng, Y. F.; Don, M. J.; Jan, W. C.; Wang, S. Y.; Ho, L. K.; Chen, C. F. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450. Drug Metabol. Dispos., 2006, 34 (5), 821-827.
60. Anzenbacherova, E.; Jancova, P.; Papouskova, B.; Lemr, K.; Luzna, P.; Veinlichova, A.; Anzenbacher, P.; Simanek, V. Silybin is metabolized by cytochrome P4502C8 in vitro. Drug Metabol. Dispos., 2007, 35 (11), 2035-2039.
61. Piver, B.; Fer, M.; Vitrac, X.; Merillon, J. M.; Dreano, Y.; Berthou, F.; Lucas, D. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem. Pharmacol., 2004, 68 (4), 773-782.
62. He, Y. Q.; Yang, L.; Liu, Y.; Zhang, J. W.; Tang, J.; Su, J.; Li, Y. Y.; Lu, Y. L.; Wang, C. H.; Yang L.; Wang, Z. T. Characterization of cardamonin metabolism by P450 in different species via HPLCESI- ion trap and UPLC-ESI-quadrupole mass spectrometry. Acta Pharmacol. Sin., 2009, 30 (10), 1462-1470.
63. Atherton, K. M.; Mutch, E.; Ford, D. Metabolism of the soyabean isoflavone daidzein by CYP1A2 and the extra-hepatic CYPs 1A1 and 1B1 affects biological activity. Biochem. Pharmacol., 2006, 72 (5), 624-631.
64. Androutsopoulos, V.; Arroo, R. R.; Wilsher, N.; Potter, G. A. Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett., 2009, 274, 54-60.
65. Walle, T.; Otake, Y. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metabol. Dispos., 2002, 30 (2), 103-105.
66. Hu, M.; Krausz, K.; Chen, J.; Ge, X.; Li, J.,Gelboin, H. L.; Gonzalez, F.J. Identification of CYP1A the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metabol. Dispos., 2003, 31, 924-931.
67. Doostdar, H.; Burke, M. D.; Mayer, R. T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology, 2000, 144 (1-3), 31-38.
68. Breinholt, V. M.; Offord, E. A.; Brouwer, C.; Nielsen, S. E.; Brosen, K.; Friedberg, T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem. Toxicol., 2002, 40 (5), 609-616.
69. Kupfer, R.; Swanson, L.; Chow, S.; Staub, R. E.; Zhang, Y. L.; Cohen, I.; Christians, U. Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101. Drug Metabol. Dispos.,2008, 36 (11), 2261-2269.
70. Liu, H. X.; Hu, Y.; He, Y. Q.; Liu, Y.; Li, W.; Yang L. Ultraperformance liquid chromatographic-electrospray mass spectrometric determination (UPLC-ESI-MS) of O-demethylated metabolite of paeonol in vitro: Assay development, human liver microsome activities and species differences. Talanta, 2009, 79 (5), 1433-1440.
71. Khojasteh-Bakht, S. C.; Chen, W.; Koenigs, L. L.; Peter, R. M.; Nelson, S. D. Metabolism of (R)-(+)-pulegone and (R)-(+)- menthofuran by human liver cytochrome P-450s: evidence for formation of a furan epoxide. Drug Metab.Dispos., 1999, 27 (5), 574-580.
72. Liu, H. X.; Hu, Y.; Liu, Y.; He, Y. Q.; Li, W. ; Yang L. Hydroxylation of tanshinone IIa in human liver microsomes is specifically catalysed by cytochrome P4502A6. Xenobiotica, 2009, 39 (5), 382-390.
73. Li, W.; Liu, Y.; He, Y. Q.; Zhang, J. W.; Gao, Y.; Ge, G. B.; Liu, H. X.; Huo, H.; Liu, H. T.; Wang, L. M.; Sun, J.; Wang, Q.; Yang L. Characterization of triptolide hydroxylation by cytochrome P450 in human and rat liver microsomes. Xenobiotica, 2008, 38 (12), 1551-1565.
74. Johnson, W. W. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance. Drug Metab. Rev., 2008, 40 (1), 101-147.
75. Zhou, S.; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.; Huang, M.; McLeod, H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 2005, 44 (3), 279-304.
76. He, S. M.; Li, C. G.; Liu, J. P.; Chan, E.; Duan, W.; Zhou, S. F. Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr. Med. Chem., 2010, 17 (33), 4072-4113.
77. Vanherweghem, J. L.; Depierreux, M.; Tielemans, C.; Abramowicz, D.; Dratwa, M.; Jadoul, M.; Richard, C.; Vandervelde, D.; Verbeelen, D.; Vanhaelen-Fastre, R.; Vanhaelen, M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet, 1993, 341 (8842), 387-391.
78. Stiborova, M.; Frei, E.; Wiessler, M.; Schmeiser, H. H. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chemical Research in Toxicology 2001, 14 (8), 1128-1137.
79. Stiborova, M.; Frei, E.; Sopko, B.; Wiessler, M.; Schmeiser, H. H. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis, 2002, 23 (4), 617-625.
80. Couet, C. E.; Hopley, J.; Hanley, A. B. Metabolic activation of pyrrolizidine alkaloids by human, rat and avocado microsomes. Toxicon, 1996, 34 (9), 1058-1061.
81. Fu, P. P.; Xia, Q.; Lin, G.; Chou, M. W. Pyrrolizidine alkaloids - genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab. Rev., 2004, 36 (1), 1-55.
82. Fang, Z. Z.; Zhang, Y. Y.; Wang, X. L.; Cao, Y. F.; Huo, H.; Yang, L. Bioactivation of herbal constituents: simple alerts in the complex system. Expert Opin. Drug Metab. Toxicol., 2011, 7 (8), 989-1007.
83. Kalgutkar, A. S.; Obach, R. S.; Maurer, T. S. Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drugdrug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab., 2007, 8 (5), 407-447.
84. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol., 2008, 82 (10), 667-715.
85. Degloda, R.; Weatlake, A.C.G. Herbal Interactions Involving Cytochrome P450 Enzymes: a mini review. Toxicol. Rev., 2004, 23 (4), 239-249.
86. Lin, J. H.; Lu, A. Y. H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet., 1998, 35 (5), 361-390.
87. Honig, P. K. Terfenadine-Ketoconazole Interaction - Pharmacokinetic and Electrocardiographic Consequences. JAMA, 1993, 269 (16), 1513-1518.
88. Fugh-Berman, A. Herb-drug interactions. Lancet, 2000, 355 (9198), 134-138.
89. Hu, Z.; Yang, X.; Ho, P. C.; Chan, S. Y.; Heng, P. W.; Chan, E.; Duan, W.; Koh, H. L.; Zhou, S., Herb-drug interactions: a literature review. Drugs, 2005, 65 (9), 1239-82.
90. Tucker, G. T.; Houston, J. B.; Huang, S. M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm. Res., 2001, 18 (8), 1071-1080.
91. Zou, L.; Harkey, M. R.; Henderson, G. L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 2002, 71 (13), 1579-1589.
92. Lim H.K, D. N., Jr., Brougham L, Elliot M, Patel K, Chan K. Automated Screening With Confirmation of Mechanism-based Inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in Pooled Human Liver Microsomes. Drug Metab. Dispos., 2005, 33, 1211-1219.
93. Ameer, B.; Weintraub, R. A. Drug interactions with grapefruit juice. Clin. Pharmacokinet., 1997, 33 (2), 103-121.
94. Goosen, T. C.; Cillie, D.; Bailey, D. G.; Yu, C.; He, K.; Hollenberg, P. F.; Woster, P. M.; Cohen, L.; Williams, J. A.; Rheeders, M.; Dijkstra, H. P. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin. Pharmacol. Therapeut., 2004, 76 (6), 607-617.
95. Yoshida, M.; Matsumoto, T.; Suzuki, T.; Kitamura, S.; Mayama, T. Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiol. Drug Saf., 2008, 17 (1), 70-75.
96. Schwarz, D.; Kisselev, P.; Schunck, W. H.; Roots, I. Inhibition of 17 beta-estradiol activation by CYP1A1: Genotype- and regioselective inhibition by St. John's Wort and several natural polyphenols. Biochimica Et Biophysica Acta-Proteins and Proteomics 2011, 1814 (1), 168-174.
97. Caceres, D. D.; Hancke, J. L.; Burgos, R. A.; Wikman, G. K. Prevention of common colds with Andrographis paniculata dried extract. A pilot double blind trial. Phytomedicine, 1997, 4 (2), 101-104.
98. Pekthong, D.; Martin, H.; Abadie, C.; Bonet, A.; Heyd, B.; Mantion, G.; Richert, L. Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide. J. Ethnopharmacol., 2008, 115 (3), 432-440.
99. Pekthong, D.; Blanchard, N.; Abadie, C.; Bonet, A.; Heyd, B.; Mantion, G.; Berthelot, A.; Richert, L.; Martin, H. Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures. Chem. Biol. Interact., 2009, 179 (2-3), 247-255.
100. Ooi, J. P.; Kuroyanagi, M.; Sulaiman, S. F.; Muhammad, T. S. T.; Tan, M. L. Andrographolide and 14-Deoxy-11, 12- Didehydroandrographolide inhibit cytochrome P450s in HepG2 hepatoma cells. Life Sci., 2011, 88 (9-10), 447-454.
101. Liu, Y.; Zhang, J. W.; Li, W.; Ma, H.; Sun, J.; Deng, M. C.; Yang, L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol. Sci., 2006, 91 (2), 356-364.
102. Liu, Y.; Li, W.; Li, P.; Deng, M. C.; Yang, S. L.; Yang, L., The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity. Biol. Pharm. Bull., 2004, 27 (10), 1555-60.
103. Liu, Y.; Ma, H.; Zhang, J. W.; Deng, M. C.; Yang, L. Influence of ginsenoside Rh1 and F1 on human cytochrome p450 enzymes. Planta Medica., 2006, 72 (2), 126-131.
104. Madgula, VLM.; Ali, Z.; Smillie, T.; Khan,IA.; Walker, LA.; Khan, SI. Alkaloids and Saponins as Cytochrome P450 Inhibitors from Blue Cohosh (Caulophyllum thalictroides) in an in vitro Assay. Planta Medica, 2009, 75 (4), 329-332.
105. Raner, G. M.; Cornelious, S.; Moulick, K.; Wang, Y.; Mortenson, A.; Cech, N. B. Effects of herbal products and their constituents on human cytochrome P450(2E1) activity. Food Chem. Toxicol., 2007, 45 (12), 2359-2365.
106. Druckova, A.; Marnett, L. J. Characterization of the amino acid adducts of the enedial derivative of teucrin A. Chem. Res. Toxicol., 2006, 19 (10), 1330-1340.
107. Salminen, K. A.; Meyer, A.; Jerabkova, L.; Korhonen, L. E.; Rahnasto, M.; Juvonen, R. O.; Imming, P.; Raunio, H. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phytomedicine, 2011, 18, 533-538.
108. Ueng, YF.;, Jan, WC., Lin, LC.; Chen, TL.; Guengerich, FP.; Chen, CF. The Alkaloid Rutaecarpine Is a Selective Inhibitor of Cytochrome P450 1A in Mouse and Human Liver Microsomes. Drug Metab. Dispos., 2003, 30, 349-353.
109. Hollenberg, P. F.; Sridar, C.; Goosen, T. C.; Kent, U. M.; Williams, J. A. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 2004, 32 (6), 587-594.
110. Beckmann-Knopp, S.; Rietbrock, S.; Weyhenmeyer, R.; Bocker, R. H.; Beckurts, K. T.; Lang, W.; Hunz, M.; Fuhr, U. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000, 86 (6), 250-256.
111. Teyssier, C.; Guenot, L.; Suschetet, M.; Siess, M. H. Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. Drug Metab. Dispos., 1999, 27 (7), 835-841.
112. Xu, H. X.; Han, Q. B.; Yang, L.; Liu, Y.; Wang, Y. L.; Qiao, C. F.; Song, J. Z.; Xu, L. J.; Yang, D. J.; Chen, S. L. Gambogic acid and epigambogic acid, C-2 epimers with novel anticancer effects from Garcinia hanburyi. Planta Medica, 2006, 72 (3), 281-284.
113. Obach, R.S. Inhibition of Human Cytochrome P450 Enzymes by Constituents of St. John's Wort, an Herbal Preparation Used in the Treatment of Depression. J. Pharmacol. Exp. Ther., 2000, 294, 88-95.
114. Lee, J.-y.; Duke, R. K.; Tran, V. H.; Hook, J. M.; Duke, C. C. Hyperforin and its analogues inhibit CYP3A4 enzyme activity. Phytochemistry, 2006, 67 (23), 2550-2560.
115. Kimura, Y.; Ito, H.; Ohnishi, R.; Hatano, T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem. Toxicol., 2010, 48, 429-435.
116. Si, DY.; W ang, Y.; Zhou, YH.; Guo, YJ.; Wang, J.; Zhou, H.; Li, ZS.; Fawcett, JP. Mechanism of CYP2C9 Inhibition by Flavones and Flavonols. Drug Metab. Dispos., 2009, 37, 629-634.
117. Chaudhary, A.; Willett, K.L. Inhibition of human cytochrome CYP1 enzymes by flavonoids of St. John's wort. Toxicology, 2006, 217, 194-205.
118. Sun, D. X.; Lu, J. C.; Fang, Z. Z.; Zhang, Y. Y.; Cao, Y. F.; Mao, Y. X.; Zhu, L. L.; Yin, J.; Yang, L. Reversible Inhibition of Three Important Human Liver Cytochrome P450 Enzymes by Tiliroside. Phytother. Res., 2010, 24 (11), 1670-1675.
119. He, L.; He, F.; Bi, HC.; Li, JK.; Zeng, S.; Luo, HB.; Huang, M. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations. Bioorg. Med. Chem. Lett., 2010, 20, 6008-6012.
120. Doostdar, H.; Burke, MD.; Mayer, RT. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology, 2000, 144, 31-38.
121. Kent, UM.; Aviram, M.; Rosenblat, M.; Hollenberg, PF. The Licorice Root Derived Isoflavan Glabridin Inhibits the Activities of Human Cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab. Dispos., 2002, 30, 709-715.
122. Sakano, K.; Kawanishi, S. Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch. Biochem. Biophys., 2002, 405 (2), 223-230.
123. Pan, Y.; Abd-Rashid, B. A.; Ismail, Z.; Ismail, R.; Mak, J. W.; Pook, P. C. K.; Er, H. M.; Ong, C. E. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica. J. Ethnopharmacol., 2010, 130 (2), 275-283.
124. He, K.; Iyer, K. R.; Hayes, R. N.; Sinz, M. W.; Woolf, T. F.; Hollenberg, P. F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol., 1998, 11 (4), 252-259.
125. Lin, H. L.; Kent, U. M.; Hollenberg, P. F. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J. Pharmacol. Exp. Ther., 2005, 313 (1), 154-164.
126. Teyssier, C.; Guenot, L.; Suschetet, M.; Siess, M. H. Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases. Drug Metab. Dispos., 1999, 27 (7), 835-841.
127. Qiu, F. R.; Zhang, R.; Sun, J. G.; A, J. Y.; Hao, H. P.; Peng, Y.; Ai, H.; Wang, G. J. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab. Dispos. 2008, 36 (7), 1308-1314.
128. Wan, C. K.; Tse, A. K.; Yu, Z. L.; Zhu, G. Y.; Wang, H.; Fong, D. W. F. Inhibition of cytochrome P450 3A4 activity by schisandrol A and gomisin A isolated from Fructus Schisandrae chinensis. Phytomedicine, 2010, 17 (8-9), 702-705.
129. Iwata, H.; Tezuka, Y.; Kadota, S.; Hiratsuka, A.; Watabe, T. Identification and Characterization of Potent CYP3A4 Inhibitors in Schisandra Fruit Extract. Drug Metab. Dispos., 2004, 32, 1351-1358.
130. Yin, J.; Sun, D. X.; Fang, Z. Z.; Zhang, Y. Y.; Cao, Y. F.; Yang, L. Inhibitory Effects of Curcumenol on Human Liver Cytochrome P450 Enzymes. Phytother. Res., 2010, 24 (8), 1213-1216.
131. Liu, Y.; Ma, H.; Zhang, J. W.; Deng, M. C.; Yang, L. Influence of ginsenoside Rh-1 and F-1 on human cytochrome P450 enzymes. Planta Medica, 2006, 72 (2), 126-131.
132. Willson, T. M.; Kliewer, S. A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov., 2002, 1 (4), 259-266.
133. Blumberg, B.; Sabbagh, W.; Juguilon, H.; Bolado, J.; van Meter, CM.; Ono, ES.; Evans, RM. SXR, a novel steroid and xenobioticsensing nuclear receptor. Genes Dev., 1998, 12, 3195-3205.
134. Xie W, Barwick,JL.; Downes, M.; Blumberg, B.; Simon, CM.; Nelson, MC.; Neuschwander-Tetri, BA.; Bruntk, EM.; Guzelian, PS.; Evans, RM. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature (Lond), 2000, 406, 435-439.
135. Kliewer, SA.; Moore, JT.; Wade, L.; Staudinger, JL.; Watson, MA.; Jones, SA.; McKee, DD.; Oliver, BB.; Willson, TM.; Zetterstrom, RH.; Perlmann, T.; Lehmann, JM. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 1998, 92, 73-82.
136. Xie, W.; Uppal, H.; Saini, SPS.; Mu, Y.; Little, JM.; Radominska- Pandya, A.; Zemaitis, MA. Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism. Drug Discov. Today, 2004, 9, 442-449.
137. Sonoda, J.; Rosenfeld, JM.; Xu, L.; Evans, RM.; Xie, W. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. Curr. Drug Metab., 2003, 4, 59-72.
138. Zhou, J.; Zhang, J.; Xie, W. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyltransferase. Curr. Drug Metab., 2005, 6, 289-298.
139. Moore, LB.; G.oodwin, B.; Jones, SA.; Wisely, GB.; Serabjit- Singh, CJ.; Willson, TM.; Collins, JL.; Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. PNAS, 2000, 97 (13), 7500-7502.
140. Wang, Z.; Gorski, J. C.; Hamman, M. A.; Huang, S. M.; Lesko, L. J.; Hall, S. D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Therapeut., 2001, 70 (4), 317-326.
141. Mu, Y.; Zhang. JN.; Zhang, SM.; Zhou HH.; Toma D.; Ren SR.; Huang L.; Yaramus M.; Baum A.; Venkataramanan R.; Xie W. Traditional Chinese Medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) Activate Pregnane X Receptor and Increase Warfarin Clearance in Rats. J. Pharmacol. Exp. Ther., 2006, 316, 1369-1377.
142. Dickins, M. Induction of cytochromes P450. Curr. Top. Med. Chem., 2004, 4 (16), 1745-1766.
143. Lin, J. H. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharmaceut. Res., 2006, 23 (6), 1089-1116.
144. Hewitt, N. J.; Lecluyse, E. L.; Ferguson, S. S. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica, 2007, 37 (10-11), 1196-1224.
145. Yu , C.; Chai, X.; Yu, L.; Chen, S.; Zeng, S. Identification of novel pregnane X receptor activators from traditional Chinese medicines. J. Ethnopharmacol., 2011, 136, 137-143.
146. Li, R. C.; Zhu, M.; Yeung, R. Y.; Lin, K. F. Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. Planta Medica, 2000, 66 (6), 521-525.
147. Yang, J. A.; Luan, X. F.; Gui, H. Y.; Yan, P.; Yang, D. F.; Song, X. L.; Liu, W.; Hu, G.; Yan, B. F. Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes. Br. J. Pharmacol. Chemother., 2011, 162 (2), 441-451.
148. Liu, Y. H.; Mo, S. L.; Bi, H. C.; Hu, B. F.; Li, C. G.; Wang, Y. T.; Huang, L.; Huang, M.; Duan, W.; Liu, J. P.; Wei, M. Q.; Zhou, S. F. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica, 2011, 41 (4), 259-280.
149. Weiss, J.; Genovese, S.; Epifano, F.; Curini, M.; Menger, D.; Zembruski, N. C. L. In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression. Phytomedicine, 2011, 18 (7), 586-591.
150. Sun, J. G.; Zhang, R.; Ma, L. P.; Wu, X. L.; Pan, G. Y.; Hao, H. P.; Zhou, F.; Jiye, A.; Liu, C. H.; Ai, H.; Shang, L. L.; Gao, H. Y.; Peng, Y.; Wan, P.; Wu, H.; Wang, G. J. Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicol. Appl. Pharmacol., 2011, 252 (1), 18-27.
151. Yu, C.; Ye, S.; Sun, H.; Liu, Y.; Gao, L.; Shen, C.; Chen, S.; Zeng, S. PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem. Biol. Interact., 2009, 177 (1), 58-64.
152. Burk, O.; Arnold, K. A.; Nussler, A. K.; Schaeffeler, E.; Efimova, E.; Avery, B. A.; Avery, M. A.; Fromm, M. F.; Eichelbaum, M. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol., 2005, 67 (6), 1954-65.
153. Harmsen, S.; Meijerman, I.; Beijnen, J. H.; Schellens, J. H. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother. Pharmacol., 2009, 64 (1), 35-43.
154. Brobst, D. E.; Ding, X.; Creech, K. L.; Goodwin, B.; Kelley, B.; Staudinger, J. L. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J. Pharmacol. Exp. Ther., 2004, 310 (2), 528-535.
155. Li, Y.; Wang, Q.; Yao XM.; Li, Y. Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways. Eur. J. Pharmacol., 2010, 640, 46-54.
156. Wojnowski, L.; Godtel-Armbrust, U.; Metzger, A.; Kroll, U.; Kelber, O. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch. Pharmacol., 2007, 375 (6), 377-382.
157. Venkataramanan, R.; Komoroski, B. J.; Zhang, S. M.; Cai, H. B.; Hutzler, J. M.; Frye, R.; Tracy, T. S.; Strom, S. C.; Lehmann, T.; Ang, C. Y. W.; Cui, Y. Y. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos., 2004, 32 (5), 512-518.
158. Hao, H. P.; Lai, L.; Zheng, C. N.; Wang, Q. O.; Yu, G.; Zhou, X. Y.; Wu, L. A.; Gong, P.; Wang, G.J. Microsomal Cytochrome P450-Mediated Metabolism of Protopanaxatriol Ginsenosides: Metabolite Profile, Reaction Phenotyping, and Structure- Metabolism Relationship. Drug Metab. Dispos., 2010, 38 (10), 1731-1739.
159. Zhang, L.; Lin, G.; Zuo, Z. Involvement of UDPglucuronosyltransferases in the extensive liver and intestinal firstpass metabolism of flavonoid baicalein. Pharm. Res., 2007, 24 (1), 81-89.
160. Wang, Q. O.; Hao, H. P.; Zhu, X. X.; Yu, G.; Lai, L.; Liu, Y. T.; Wang, Y. X.; Jiang, S.; Wang, G. J. Regioselective Glucuronidation of Tanshinone IIa after Quinone Reduction: Identification of Human UDP-Glucuronosyltransferases, Species Differences, and Interaction Potential. Drug Metab. Dispos., 2010, 38 (7), 1132-1140.
161. Chen, Z.; Chen, M.; Pan, H.; Sun, S.; Li, L.; Zeng, S.; Jiang, H. Role of catechol-O-methyltransferase in the disposition of luteolin in rats. Drug Metab. Dispos., 2011, 39 (4), 667-674.
162. Zhang, L.; Zuo, Z.; Lin, G. Intestinal and hepatic glucuronidation of flavonoids. Mol. Pharm., 2007, 4 (6), 833-845.
163. Morris, M. E.; Zhang, S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci., 2006, 78 (18), 2116-2130.
164. Watkins, P. B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 1994, 4 (4), 171-184.
165. Streetman, D. S.; Bertino, J. S.; Nafziger, A. N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics, 2000, 10 (3), 187-216.
166. Benet, L. Z. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interv., 2005, 5 (2), 79-83.
167. Masica, A. L.; Mayo, G.; Wilkinson, G. R. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin. Pharmacol. Therapeut., 2004, 76 (4), 341-349.